Skip to main navigation Header - Right - Links Contact Us Social Links Press Releases Press Contact Anja Heuer Corporate Communications, Immatics N.V. media@immatics.com +49 89 540 415 606 Sidebar Social Links Immatics Factsheet English Immatics Therapeutic Approach (animation) Always up to date: Receive posts from us and our partners via our Twitter profile. Find out more about Immatics on LinkedIn with our News, Events & Press Releases. English German Year 2021 Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update Interim data update at SITC for ongoing ACTe ngine ® IMA203 trial targeting PRAME demonstrated clinical responses a cross multiple solid tumor types during dose escalation phase Immatics to i nitiate three expansion cohorts for IMA203 targeting PRAME : monotherapy, combination with checkpoint Nov 16, 2021 PDF Version Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid Nov 09, 2021 PDF Version Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on its Nov 01, 2021 Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update ACTengine ® patient recruitment remains on track ; a s of en d of July, a total of 2 7 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indications TCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical Aug 10, 2021 PDF Version Immatics Announces Changes to its Board of Directors Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced changes to its Board of Directors. May 26, 2021 PDF Version Immatics Announces First Quarter 2021 Financial Results and Business Update Data update for ongoing ACTengine® IMA200 clinical trial series demonstrate d first anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation Next ACTengine® data update for dose level s 2 and 3 on track for H2 2021 P reclinical proof-of-concept for May 18, 2021 PDF Version Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME Immatics ’ second TCR Bispecific s program IMA402 demonstrate s t umor cell killing in vitro and complete regression s of established tumor s in a n in vivo tumor model IMA402 targets a n Immatics - validated peptide derived from PRAME, one of the most frequent ly expressed intracellular cancer May 11, 2021 PDF Version Immatics Announces Full Year 2020 Financial Results and Corporate Update Phase 1a data update from clinical ACTengine ® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients Enrollment across clinical ACTengine ® IMA200 trial series continues to scale up Cash and cash equivalents as well as other Mar 30, 2021 PDF Version Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs Company to host conference call on Wednesday, March 17 at 8:30 am EST · First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation · Tumor shrinkage observed in 8 out of 10 patients including one partial response consistent with robust Mar 17, 2021 PDF Version IR Toolkit PRINT PAGE EMAIL ALERTS RSS FEEDS CONTACTS Immatics N.V. Immatics Biotechnologies GmbH Paul-Ehrlich-Str. 15 72076 Tuebingen Germany Phone: +49 7071 5397-0 Fax: +49 7071 5397-900 E-Mail: info@immatics.com Immatics US, Inc. 2201 W. Holcombe Blvd., Suite 205 Houston, Texas 77030 Business line: +1 346 204-5400 Fax line: +1 346 204-5391 E-Mail: info@immatics.com Immatics Biotechnologies GmbH Machtlfinger Str. 11 81379 Munich Germany Phone: +49 (89) 540415-0 Fax: +49 (89) 540415-905 E-Mail: info@immatics.com Footer Links Imprint Privacy Policy English Privacy Policy German Privacy Settings Social Links © 2021 Immatics Biotechnologies GmbH By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Accept All Cookies Privacy Settings